Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

[Pharmacological vitreolysis].

C Haritoglou1, A Kampik

  • 1Augenklinik , Ludwig-Maximilians-Universität, Mathildenstr. 8, 80336, München, Deutschland, Christos.haritoglou@med.uni-muenchen.de.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|September 19, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Current treatment strategies for vitreomacular traction and macular holes: a survey of retinal specialists in Germany].

Die Ophthalmologie·2024
Same author

[Tonometry and pachymetry to evaluate fluctuations of intraocular pressure in the context of SCUBA diving].

Die Ophthalmologie·2023
Same author

[Erratum to: Optical coherence tomography biomarkers in epimacular membranes and vitreomacular traction syndrome].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Optical coherence tomography biomarkers in epimacular membranes and vitreomacular traction syndrome].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Biomarkers in full-thickness and lamellar defects of the macula].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Erratum to: Macular changes in optic disc pits-Optic disc pit maculopathy (ODP-M). Pathophysiology and possibilities of surgical treatment].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same journal

["DOG 2020 online" - for the first time in the von Graefe year].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2024
Same journal

[Are organ and co-cultures an alternative to animal models in ophthalmology?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Pediatric corneal opacities : Even small improvements provide lifelong help].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Myxoma of the conjunctiva].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
See all related articles

Posterior vitreous detachment (PVD) can cause vision problems. Pharmacological vitreolysis offers a non-surgical option to treat conditions like vitreomacular traction and macular holes by releasing vitreous adhesions.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vitreoretinal Interface

Context:

  • Posterior vitreous detachment (PVD) is a common age-related condition.
  • Incomplete PVD can lead to pathological vitreous adhesions and tractional forces.
  • These forces can cause retinal breaks, detachment, and macular pathologies.

Purpose:

  • To explore the role of pharmacological vitreolysis as a non-surgical treatment for vitreoretinal interface abnormalities.
  • To evaluate its efficacy in conditions like vitreomacular traction syndrome and macular holes.
  • To investigate its potential use in exudative macular diseases and as an adjunct to surgery.

Summary:

  • Pars plana vitrectomy is a current surgical treatment for PVD-related complications.
  • Pharmacological vitreolysis uses enzyme injections to dissolve vitreous adhesions, releasing tractional forces.

More Related Videos

Whole Vitreous Humor Dissection for Vitreodynamic Analysis
04:41

Whole Vitreous Humor Dissection for Vitreodynamic Analysis

Published on: May 24, 2015

Related Experiment Videos

Last Updated: May 7, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Whole Vitreous Humor Dissection for Vitreodynamic Analysis
04:41

Whole Vitreous Humor Dissection for Vitreodynamic Analysis

Published on: May 24, 2015

  • This non-surgical approach has shown success in treating certain forms of vitreomacular traction and macular holes.

    • Impact:

    • Pharmacological vitreolysis presents a less invasive alternative to surgery for specific retinal conditions.
    • It offers a potential new treatment avenue for patients experiencing visual impairment due to vitreoretinal traction.
    • Further research is ongoing to expand its therapeutic applications.